Fortnightly or fractionated weekly docetaxel–cisplatin–5‐FU as first‐line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study

Fortnightly or fractionated weekly docetaxel–cisplatin–5‐FU as first‐line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study

Abstract Background While docetaxel/cisplatin/5‐fluorouracil (DCF) outperforms CF in first‐line gastric adenocarcinoma, toxicity remains an issue. Methods This multicenter phase II trial randomized chemonaïve metastatic gastric adenocarcinoma patients to fractionated weekly DCF (D 40 mg/m2, C 35 mg/...

Full description

Bibliographic Details
Main Authors: Amélie Deleporte, Marc Van den Eynde, Frédéric Forget, Stéphane Holbrechts, Thierry Delaunoit, Ghislain Houbiers, Hassan R. Kalantari, Stéphanie Laurent, Erik Vanderstraeten, Marc De Man, Philippe Vergauwe, Marylene Clausse, Jacques Van Der Auwera, Lionel D’Hondt, Pascal Pierre, Bjorn Ghillemijn, Angelique Covas, Marianne Paesmans, Lieveke Ameye, Ahmad Awada, Francesco Sclafani, Alain Hendlisz
Format: Article
Language:English
Published: Wiley 2021-07-01
Series:Cancer Medicine
Subjects:
5‐FU
cisplatin
docetaxel
fortnightly
gastric cancer
gastroesophageal cancer
Online Access:https://doi.org/10.1002/cam4.3976

Internet

https://doi.org/10.1002/cam4.3976

Similar Items